ArticleJournal of virology2010
Delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection.
Article in Journal of virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Neonatal Immune Responses to Respiratory Viruses.Frontiers in immunology · 2022Review
- Prior respiratory syncytial virus infection reduces vaccine-mediated Th2-skewed immunity, but retains enhanced RSV F-specific CD8 T cell responses elicited by a Th1-skewing vaccine formulation.Frontiers in immunology · 2022Article
- Enhanced IL-2 in early life limits the development of TFH and protective antiviral immunity.The Journal of experimental medicine · 2021Article
- Strategies for active and passive pediatric RSV immunization.Therapeutic advances in vaccines and immunotherapy · 2021Review
- New mouse model of pulmonary hypertension induced by respiratory syncytial virus bronchiolitis.American journal of physiology. Heart and circulatory physiology · 2018Article
- Neonatal Immunity, Respiratory Virus Infections, and the Development of Asthma.Frontiers in immunology · 2018Review
- Article
- Alveolar macrophages support interferon gamma-mediated viral clearance in RSV-infected neonatal mice.Respiratory research · 2015Article
- Immunity to RSV in Early-Life.Frontiers in immunology · 2014Review
- Delayed sequelae of neonatal respiratory syncytial virus infection are dependent on cells of the innate immune system.Journal of virology · 2014Article
- Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice.Journal of virology · 2013Article
- Neonatal antibody responses are attenuated by interferon-γ produced by NK and T cells during RSV infection.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- STAT3-mediated IL-17 production by postseptic T cells exacerbates viral immunopathology of the lung.Shock (Augusta, Ga.) · 2012Article
- Preexposure to CpG protects against the delayed effects of neonatal respiratory syncytial virus infection.Journal of virology · 2012Article
- Depletion of alveolar macrophages prolongs survival in response to acute pneumovirus infection.Virology · 2012Article
- Article
- Neonatal CD8 T-cell hierarchy is distinct from adults and is influenced by intrinsic T cell properties in respiratory syncytial virus infected mice.PLoS pathogens · 2011Article
- Immunomodulation with IL-4R alpha antisense oligonucleotide prevents respiratory syncytial virus-mediated pulmonary disease.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
Respiratory syncytial virus (RSV) is the main cause of bronchiolitis, the major cause of hospitalization of infants. An ideal RSV vaccine would be effective for neonates, but the immune responses of infants differ markedly from those of adults, often showing a bias toward T-helper 2 (Th2) responses and reduced gamma interferon (IFN-gamma) production. We previously developed recombinant RSV vectors expressing IFN-gamma and interleukin-4 (IL-4) that allow us to explore the role of these key Th1 and Th2 cytokines during infection. The aim of the current study was to explore whether an immunomodulation of infant responses could enhance protection. The expression of IFN-gamma by a recombinant RSV vector (RSV/IFN-gamma) attenuated primary viral replication in newborn mice without affecting the development of specific antibody or T-cell responses. Upon challenge, RSV/IFN-gamma mice were protected from the exacerbated disease observed for mice primed with wild-type RSV; however, antiviral immunity was not enhanced. Conversely, the expression of IL-4 by recombinant RSV did not affect virus replication in neonates but greatly enhanced Th2 immune responses upon challenge without affecting weight loss. These studies demonstrate that it is possible to manipulate infant immune responses by using cytokine-expressing recombinant viruses and that neonatal deficiency in IFN-gamma responses may lead to enhanced disease during secondary infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.